CD274 and neoplasm: These include variations in detection platforms and assays, especially the specific diagnostic antibody in immunohistochemistry and the PD-L1 staining method; the discrepancies of quality for tumor specimens and the approach for sampling gathering; different threshold values used to define PD-L1 positivity; and the spatial and temporal heterogeneity of PD-L1 expression (32–35).